A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pregant or lactating women or women planning to become pregnant during the study

current diagnosis of asthma

other respiratory disorders other than COPD

other diseases/abnormalities that are uncontrolled including cancer not in remission for at least 5 years

chest x-ray or CT scan with clinically significant abnormalities not believed to be due to COPD

hypersensitivity to anticholinergics, beta-agonists, lactose/milk protein or magnesium stearate or medical conditions associated with inhaled anticholinergics

hospitalization for COPD or pneumonia within 12 weeks prior to Visit 1

lung volume reduction surgery within 12 months prior to Visit 1

abnormal and clinically significant ECG at Visit 1

abnormal and clinically significant Holter monitor finding at Visit 1

significantly abnormal finding from laboratory tests at Visit 1

unable to withhold albuterol/salbutamol and/or ipratropium bromide at least 4 hours prior to spirometry at each visit

use of depot corticosteroids within 12 weeks of Visit 1

use of oral or parenteral corticosteroids within 6 weeks of Visit 1

use of anitbiotics for lower respiratory tract infection within 6 weeks of Visit 1

use of cytochrome P450 3A4 inhibitors within 6 weeks of Visit 1

us of long-acting beta-agonist (LABA)/inhaled corticosteroid (ICS) products if LABA/ICS therapy is discontinued completely within 30 days of Visit 1

use of ICS at a dose of \>10000mcg/day of fluticasone propionate or equivalent within 30 days of Visit 1

initiation or discontinuation of ICS within 30 days of Visit 1

use of tiotropium within 14 days of Visit 1

use of roflumilast within 14 days of Visit 1

use of theophyllines within 48 hours of Visit 1

use of oral leukotriene inhibitors within 48 hours prior to Visit 1

use of long-acting oral beta-agonists within 48 hours of Visit 1

use of short-acting oral beta-agonists within 12 hours of Visit 1

use of inhaled long-acting beta-agonists within 48 hours prior to Visit 1

use of LABA/ICS combination products only if discontinuing LABA therapy and switching to ICS monotherapy within 48 hours of Visit 1 for the LABA component

use of sodium cromoglycate or nedocromil sodium within 24 hours of Visit 1

use of inhaled short acting beta-agonists within 4 hours of Visit 1

use of inhaled short-acting anticholinergics within 4 hours of Visit 1

use of inhaled short-acting anticholinergic/short-acting beta2-agonist combination products within 4 hours of Visit 1

use of any other investigational medication within 30 days or 5 drug half-lives (whichever is longer) of Visit 1

long-term oxygen therapy prescribed for \>12 hours per day

regular use of short-acting bronchodilators

use of CPAP or NIPPV

participation in the maintenance phase of a pulmonary rehabilitation program

known or suspected history of alcohol or drug abluse with 2 years prior to Visit 1

anyone affiliated with the investigator site (e.g., investigator, study coordinator, etc.)

previous use of GSK573719, GW642444 , GSK573719/GW642444 combination, GSK233705/GW642444 combination, or Fluticasone Furoate/GW642444 combination

What this study is about